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Abstract
Background: Pathogen-associated molecular patterns (PAMPs) are structural components of pathogens such as
lipopolysaccharide (LPS) and peptidoglycan (PGN) from bacterial cell walls. PAMP-recognition by the host results in
an induction of defence-related genes and often the generation of an inflammatory response. We evaluated both
the transcriptomic and inflammatory response in trout (O. mykiss) macrophages in primary cell culture stimulated
with DAP-PGN (DAP; meso-diaminopimelic acid, PGN; peptidoglycan) from two strains of Escherichia coli (PGN-K12
and PGN-O111:B4) over time.
Results: Transcript profiling was assessed using function-targeted cDNA microarray hybridisation (n = 36) and
results show differential responses to both PGNs that are both time and treatment dependent. Wild type E. coli
(K12) generated an increase in transcript number/diversity over time whereas PGN-O111:B4 stimulation resulted in
a more specific and intense response. In line with this, Gene Ontology analysis (GO) highlights a specific
transcriptomic remodelling for PGN-O111:B4 whereas results obtained for PGN-K12 show a high similarity to a
generalised inflammatory priming response where multiple functional classes are related to ribosome biogenesis or
cellular metabolism. Prostaglandin release was induced by both PGNs and macrophages were significantly more
sensitive to PGN-O111:B4 as suggested from microarray data.
Conclusion: Responses at the level of the transcriptome and the inflammatory outcome (prostaglandin synthesis)
highlight the different sensitivity of the macrophage to slight differences (serotype) in peptidoglycan structure.
Such divergent responses are likely to involve differential receptor sensitivity to ligands or indeed different receptor
types. Such changes in biological response will likely reflect upon pathogenicity of certain serotypes and the
development of disease.
Background
Detection of pathogens by host organisms requires
direct contact between host PRRs (pattern recognition
receptors) and pathogen-associated molecular patterns
(PAMPs) where PAMP-PRR interactions subsequently
dictate the development of the host immune response
[1,2]. PAMPs such as the lipopolysaccharides (LPS) and
peptidoglycans (PGN), both bacterial cell wall compo-
nents, have been directly implicated in the induction of
the host immune response across the vertebrata [3-9].
Peptidoglycan and related fragments are recognised by
the host and induce diverse biological effects, including
inflammation, leukocytosis, or enhanced immune
responses [10-13]. Like LPS, peptidoglycan, including its
minimal immunomodulatory subunit, muramyl dipep-
tide, can bind to the CD14 receptor of target cells in
mammals [14-16] although peptidoglycan does not bind
to LBP or BPI [17,18]. PGN’s do not activate TLR4-
mediated signal transduction but do activate both the
TLR2 and NOD pathways [19-24].
In Drosophila, PGN recognition is achieved by the
Toll or Immune deficiency (Imd) pathways, at least in
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part, through peptidoglycan recognition proteins
(PGRPs) [25,26]. Both pathways share common features
with mammalian Toll-like receptor (TLR) and tumour
necrosis factor-a (TNF-a) receptor signalling cascades
that regulate NF-B activation [27-29]. In vivo studies
in the zebrafish have shown that the PGRP response is
essential for successful responses to bacterial infection
[30]. Recently, PGN in trout macrophages has been
shown to be the major stimulatory component in crude
LPS preparations characterised by an increase in cyto-
kine mRNAs, IL-1b and IL-6, and release of inflamma-
tory products as prostaglandin E2 (PGE2) [9]. However,
studies addressing different responses to serotype-
specific PGNs are scarce throughout the vertebrata
including mammals.
PGN may account for approximately one-half of the
cell wall mass in gram-positive bacteria whereas in
gram-negative bacteria only a relatively thin PGN layer
in the periplasmic space is present [31,32]. Gram-
negative peptidoglycan contains meso-diaminopimelic
acid (DAP) as the major peptide group that is directly
cross-linked whereas most gram-positive bacteria have
L-lysine as the third amino acid (Lys-type). These Lys-
type peptides are cross-linked through an inter-peptide
bridge that varies in length and amino acid composition
in different bacteria [32-34].
As the structure and composition of the microbial
motif has an important role in host sensing and minor
modifications in structure can influence the immune
response [35-38] we explored the response of differen-
tiated trout macrophages in cell culture to different
PGNs from E. coli of different strains (K12 and O111:
B4). Our results show that trout macrophages differen-
tially respond to different PGNs at the level of the
transcriptome by either differentially activating RNA
transcripts related to prostaglandin synthesis resulting
in the liberation of prostaglandin’s (PGN-O111:B4) or
by generating a non-defined inflammatory response,
(PGN-K12).
Methods
Animals and Materials
Healthy adult specimens (160 g mean weight) of rain-
bow trout (O. mykiss) were purchased from a commer-
cial hatchery (Piscifactoria Andrés, St Privat, Girona)
and held in recirculating freshwater stock tanks (300 L)
in the aquarium facilities at the Universitat Autònoma
de Barcelona. Fish were kept at 15°C with a 12 h light/
12 h dark photoperiod cycle, and were fed with a main-
tenance ratio of about 0.5% body weight per day. Water
quality indicators (dissolved oxygen, ammonia, nitrite,
pH) were analysed periodically.
DMEM and FBS were purchased from PAA Labora-
tories (Spain). Poly-D-lysine was purchased from Sigma
(Tres Cantos, Madrid). Primocin, and PGN preparations
(PGN E. coli K12, O111:B4) were purchased from Invi-
vogen (Nucliber, Spain). Cell strainers and plasticware
were purchased from BD Biosciences (Madrid, Spain).
Gel Green was purchased from Biotium (Labnet, Spain).
Prostaglandin E2 and D2 enzyme immunoassay (EIA) kit
was from Cayman (Scharlab, Spain).
Cell culture and stimulation
The experimental protocols used for head kidney isola-
tion have been reviewed and approved by the Ethics and
Animal Welfare Committee of the Universitat Auton-
oma de Barcelona, Spain. After anaesthetising the fish in
3-aminobenzoic acid ethyl ester (0.1 g/L), animals were
sacrificed and the head kidney was dissected out. Trout
macrophages were isolated as previously described [39].
Before stimulation, differentiated macrophages were
incubated in serum free medium for 3 h. For stimula-
tion, the medium of each well was removed and fresh
medium containing the indicated concentrations of
PGN were added and the cultures were incubated for
the indicated times.
RNA extraction and complementary DNA (cDNA)
synthesis
Total RNA was extracted from cell cultures using 1 mL
of TriReagent (Molecular Research Center) per well cell
culture, following the manufacturer’s instructions.
Quantification was carried out with a Nanodrop1000
(Thermo Scientific) and the quality of the RNA was
checked with a Bioanalyzer (Agilent technologies). All
RNA samples had a RIN value >7. Total RNA (2 μg)
was used to synthesise cDNA with SuperScript III Tran-
scriptase (Invitrogen) and oligo-dT primer (Promega).
Measurement of PGE2 and PGD2 levels
Supernatants from stimulated cell cultures (triplicates)
from 3 different fish were recovered, centrifuged and
stored at -80°C until use. Measurement of PGE2 and
PGD2 levels was completed with a monoclonal EIA
according to the manufacturer’s instructions. The pros-
taglandin kit detection limit was 8 pg/mL. Prior to pros-
taglandin determination supernatants were diluted
five times in EIA assay buffer. The same macrophage
cells were used to obtain total RNA for the determina-
tion of COX-2 and Prostaglandin D synthase gene
expression as well as the supernatants for PGE2-PGD2
determination.
Microarray analysis
The design of the microarray is described in detail
elsewhere [40,41] and a full description of the platform
and data presented in this manuscript are accessible
through the public GEO depositories (accession number
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GPL6154 and GSE22330). The genes were selected by
functional classes; random clones from common and
subtracted cDNA libraries 1800 genes printed in six
replicates each were compared with the known vertebrate
proteins using BlastX; overall, the platform was enriched
in a number of functional classes, such as immune
response (236 genes), signal transduction (245 genes),
receptor activity (126 genes), apoptosis (120 genes), cell
cycle (70 genes), protein catabolism (90 genes), folding
(70 genes), response to oxidative stress (39 genes), stress
and defence response (145 and 105 genes, respectively),
and chaperone activity (41 genes). Total RNA was
extracted from cell cultures using 1 mL of TriReagent
(Molecular Research Centre) per well, following the man-
ufacturer’s instructions, the quantity and integrity was
analysed by Experion RNA StdSens Analysis Kit (Bio-
Rad). Microarray analyses were conducted in pooled
samples (see experimental design of microarray assay).
A dye-swap design of hybridisation was applied. In ana-
lyses of infected immune cells, the non-infected cells
were used as a control. Each sample was analysed with
two slides. Scanning was performed with Alphascan
(High Performance Dual-Laser Scanner for Microarray
Slides from Alpha Innotech and images were processed
with VisionLite (ThermoSpectronic). The measurements
in spots were filtered by criteria I/B ≥ 3 and (I-B)/(SI +
SB) ≥ 0.6, where I and B are the mean signal and back-
ground intensities and SI, SB are the standard deviations.
After subtraction of mean background, locally weighted
non-linear regression (Lowess) normalisation [42] was
performed separately for each slide. To assess differential
expression of genes, the normalised log intensity ratios
were analysed with Student’s t-test (p < 0.01). The Baye-
sian modification to the false discovery rate (FDR) was
used to correct for multiple comparison tests, estimating
the q-value for the set of differentially expressed genes
[43]. The functional categories of Gene Ontology [44]
were compared with regulated genes (p < 0.01) by the
sums of ranks (Student t-test p < 0.05). The statistical
significance of over-represented functional categories,
showing the differential expression in the experiment
grouped by functional classes compared with all genes an
GO categories from the chip, was assessed using the Chi
square test with Yates correction (p < 0.05).
Real-Time quantitative PCR and validation
In order to verify microarray results, real-time PCR
(qRT-PCR) was carried out. Two micrograms of the
individuals RNA was used to synthesise cDNA with
SuperScript III RNase Transcriptase (Invitrogen) and
oligo-dT primer (Promega). As a house-keeping gene,
18S was amplified from the same cDNA samples. For
different gene expression analysis specific primers were
used (Additional file 1). Real-time PCR reactions were
carried out in a 25 μL reaction with SYBR Green I
(Stratagene) using a 1:25 dilution of the cDNA and
250 nM of primers. Quantitative qRT-PCR was performed
using a Mx 3000P System (Stratagene) and quantification
was done according to the Pfaffl method corrected for effi-
ciency for each primer set [45]. Values for each sample
were expressed as “fold differences”, calculated relative to
controls group and normalised for each gene against those
obtained for the house keeping gene 18S.
Experimental design
Microarray analysis
macrophage cell cultures isolated from 84 animals were
stimulated with PGNs from E.coli O111:B4 and K12
strains and compared to parallel control cultures (with-
out stimulation). Cell cultures were individually stimu-
lated with both peptidoglycans for 1, 6 and 12 h (12 by
PGN and time, n = 72), and 12 control cultures (total;
n = 84). Individuals RNAs were grouped into three
pools from 4 cell cultures for each time point (1, 6, and
12 h). The transcriptomic response was analysed by
microarray assay, and divided in three experimental
time points named early (1 h), median (6 h) and late
stage (12 h). The analysis was carried out with common
genes expressed within three replicate pools over the
control (GDE one way ANOVA p > 0.01). The qRT-
PCR validation assay was conducted with total RNA
from late stage cell cultures.
Time Course
macrophage cell cultures isolated from 9 animals were
stimulated with PGN O111:B4 and K12 during 0,
30 min, 1, 3, 6, and 12 h (10 μg/mL). The mRNA abun-
dance of COX-2 (or prostaglandin endoperoxide
synthase 2) and PTGDS was measured by qRT-PCR,
prostaglandin release (PGE2-PGD2) were measured
using a prostaglandin EIA assay (Cayman). Three indivi-
dual replicates were made for each peptidoglycan stimu-
lation. The control group was non-stimulated cell
cultures (n = 3).
Dose-Response
macrophage cell cultures isolated from 9 animals were
stimulated with PGN from the E. coli strains 0111:B4
and K12. The treatment was conducted overnight (12 h)
with different concentrations, 0, 0.1 and 10 μg/mL, of
PGNs. Expression of COX-2 and PTGDS mRNAs was
measured by qRT-PCR, prostaglandin release (PGE2-
PGD2) were measured using a prostaglandin EIA assay
(Cayman). Three individual replicates were made for
each peptidoglycan stimulation. The control group was
non-stimulated cell cultures (n = 3).
Statistical analysis
All statistical analysis was conducted with the software
SPSS Statistic 17.0. The relationship between intensity
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of expression and time was examined and tested for sig-
nificant differences between the PGNs with covariance
analysis (ANCOVA) using the transcriptomic magnitude
as co-variable, followed by one-way ANOVA analysis for
up- or down regulated transcripts. The Student t-test
was made to explore the difference between the expres-
sion registered in the microarray assay and the qRT-
PCR (Additional file 2). Two-way ANOVAs were made
to compare the differences between COX-2 and PTGDS
expression and prostaglandin release in the time-course
and dose-response assay.
Results
Global comparisons of the transcriptomic response to
PGN (microarray analysis at 1, 6, and 12 hours)
Microarray analyses were evaluated using a salmonid-
specific targeted cDNA microarray containing 1800
cDNAs enriched with immune system related genes
(SFA 2.0). Gene expression profiles obtained highlighted
a marked contrast in the macrophage response to PGN
purified from E. coli (PGN-O111:B4 and K12). Samples
were taken over time early (1 h), median (6 h) and late
stage (12 h) and separate one-way ANOVAs (p > 0.01)
were conducted to identify differentially expressed tran-
scripts over the control (GDE). Transcripts expressed
within all three biological replicates were used to analyse
changes for both treatment (PGN) and time stage
(Additional files 3, 4, 5, 6, 7, 8). The kinetics of the
response obtained from peptidoglycans derived from
K12 or O111:B4 were significantly different in both
transcript number (total number of differentially
expressed transcript over the control, one-way ANOVA
p < 0.01) and intensity (fold change FC >2) (Figure 1).
In total 819 transcripts were differentially expressed
(GDE) in both treatments over the control (all cDNAs
expressed on the array), with 270, 221 and 328 in the
early stage, median and late stages respectively (Figure 1,
and Additional file 3, 4, 5, 6, 7, 8, 9). Stimulation with
PGN-O111:B4 revealed a significant peak in intensity at
the median stage (130 transcripts one-way ANOVA p <
0.01 and FC >2; 92) and a strong and intense response
was maintained throughout (FC >2; 51, 92 and 72 at 1,
6 and 12 h respectively). In contrast PGN-K12 induced
a significant diversity of transcripts (magnitude) over
time, note a decrease at 6 h, where the response inten-
sity although high at 1 h (FC >2; 134 transcripts) signifi-
cantly decreased through time where late stage
transcripts with FC >2 represent only 17% of the early
stage total (Figure 1, Additional file 9). Regression analy-
sis (up regulated genes ANCOVA, F5, 68 = 1.178 p >
0.05, followed by two-way ANOVA, F2, 68 = 27.124: p <
0.05; down regulated genes ANCOVA, F5, 68 = 2.303:
p > 0.05, followed by two-way ANOVA, F2, 68 = 37.124:
p < 0.05) (Additional file 10, and 11) highlights that a
stronger induction of gene expression and likely more
directed response is obtained with PGN-O111:B4
challenge.
Qualitative comparisons of the transcriptomic response to
PGN: Differentially expressed transcripts in early, median,
and late stages of activation
Early stage
A higher number of induced transcripts were observed
with PGN-K12 treatment in respect to PGN-B4 high-
lighting a common down-regulation of inflammatory
processes (Table 1 and 2). Major differences could also
be identified in ligand recognition where macrophages
stimulated with PGN-K12 up-regulated BPI binding pro-
tein (BPI). In fish, BPI has been suggested to be involved
in LPS binding and recognition [46] whereas PGN-B4
stimulation led to up-regulation of antigen-processing
including MHC I, and MARCO. The alternative spliced
Figure 1 Characterisation of the transcriptomic response. A; Venn diagram representing mRNA transcripts differentially expressed over
control during PGN-O111:B4 and PGN-K12 challenges throughout the time (early, median and late stage). The area of the circles is scaled to the
number of transcripts (one way ANOVA p < 0.01) and the fold change (FC >2) expressed in each stage. Black circles: 69, 130, 86 number of
transcripts differentially expressed under PGN-O111:B4 treatment. White circles: 173, 64, 219 number of transcripts differentially expressed under
PGN-K12 challenge.
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form of MARCO, Cysteine-rich protein 1, that also
recognises bacterial cell wall PAMP’s was co-ordinately
down-regulated [47]. Transcripts related to the inflam-
matory response were down regulated under both PGN
challenges including for PGN-B4; N-acetylmuramoyl-L-
alanine amidase (bactericidal activity), PGLYPR6 and
peroxiredoxin (Table 1) and for PGN-K12; NF-B inhi-
bitor alpha-1 and arachidonate 5-lipoxygenase (Table 2).
Microsomal glutathione S-transferase, a precursor for
leukotriene and prostaglandin production [48] was
down-regulated by both treatments. Interestingly,
annexin A1-1 was strongly up-regulated (FC; 9.8) in
response to PGN-K12. This transcript has been
suggested to have anti-inflammatory activity due to its
phospholipase A2 (essential for inflammatory prosta-
glandin production) inhibitory activity [49] (Table 2 and
Additional file 6).
Median stage
Of note at the median stage is that PGN-B4 induces a
co-ordinated increase in pro-inflammatory and cellular
defence activity with increased intensity (Table 1 and 2).
Mediators of inflammatory prostaglandin production are
up-regulated highlighted by increased arachidonate 5
lipoxygenase mRNA synthesis. In parallel, cathepsin
transcripts (protease activity) (n = 6), PGLYPR6 (ami-
dase) and the interleukin enhancer 3 mRNA (regulates
interleukin production during infectious processes (e.g.,
[50]), were also up-regulated. PGN-K12 stimulation at
this point is highlighted by a strong down-regulation of
transcript diversity, including cell adhesion, defence
response, cell homeostasis and metabolism, with almost
all observed early stage transcripts returning to base-line
conditions (Table 1 and 2). Potentially of importance is
the up-regulation of the transcription factor CCAAT/
enhancer binding protein b (C/EBP-b) mRNA by PGN-
K12. C/EBP-b has been shown to be intimately linked
to immune and inflammatory processes and regulates
the transcription of the pro-inflammatory cytokine,
interleukin-6. On the other hand, the tumour necrosis
factor (TNF) decoy receptor, which inhibits apoptosis,
and NF-B inhibitor alpha-3 were strongly up-regulated
in addition to an abrupt increase in BPI with PGN-B4.
Late stage
For PGN-B4 a defined response was observed after 12 h
of stimulation where the prostaglandin endoperoxide
synthase-2 (COX-2), and prostaglandin D synthase, both
linked to the synthesis of inflammatory prostaglandins,
were strongly up-regulated (Table 1). COX-2 (prostaglan-
din endoperoxide synthase-2) catalyses the conversion of
arachidonic acid to prostaglandin (PGH2) [51,52], and
prostaglandin D synthase (PTGDS) catalyses the conver-
sion of PGH2 to prostaglandin D2 (PGD2) [53,54]. Signal-
ling components for TLR pathways are also up-regulated
by PGN-B4 including the MAPK pathways and myeloid
differentiation primary response (MyD88) mRNA, an
adapter protein between TLR and the transcription factor
NF-B. Interestingly these components plus the serine/
threonine-protein kinase 2 are required to respond to
microbial ligands [55]. TNF decoy receptor is maintained
up-regulated highlighting the anti-apoptotic response of
PGN-B4 activated macrophages. TNF-a is secreted into
the culture medium as soon as 1 h after PGN treatment
[MacKenzie et al, unpublished results]. In contrast to the
strong inflammatory profile obtained for PGN-B4 the
PGN-K12, response at 12 h appears related to biological
themes associated with energy, protein metabolism and
cellular homeostasis at a low level of intensity (Table 2
Table 1 Summary of selected transcripts expressed after
challenges with PGN-O111:B4
Early Median Late
Antigen presenttion Mean SD Mean SD Mean SD
MHC class I heavy chain-1 4.92 2.35 3.27 1.67 n/s n/s
Macrophage receptor MARCO 2.07 0.56 5.02 1.75 n/s n/s
Cysteine-rich protein 1 -3.59 0.74 n/s n/s n/s n/s
BPI binding protein n/s n/s 11.93 5.78 n/s n/s
Cell adhesion and proliferation
CD166 1.79 0.35 4.99 2.97 3.06 1.48
Cytokines and Chemokines
C-C chemokine receptor type 3 4.25 3.47 n/s n/s n/s n/s
Chemokine receptor CXCR4 n/s n/s -4.24 1.01 n/s n/s
Cellullar defense response
N-acetylmuramoyl-L-alanine
amidase
-1.60 0.05 1.46 0.03 1.46 0.17
Peroxiredoxin 1-1 -2.98 1.42 1.30 0.76 1.74 0.30
Interleukin enhancer-binding
factor 3
n/s n/s 2.39 1.47 n/s n/s
TNF decoy receptor n/s n/s 11.42 3.86 12.09 10.98
NF-kappaB inhibitor alpha-3 n/s n/s 9.24 6.05 n/s n/s
Myeloid differentiation primary
response
n/s n/s n/s n/s 1.56 0.29
Phosphotyrosine SH2 domain n/s n/s n/s n/s 2.86 1.17
Procathepsin L-1 n/s n/s 4.11 1.67 n/s n/s
Procathepsin L-2 n/s n/s 3.47 1.28 n/s n/s
Cathepsin B-2 n/s n/s 3.36 2.29 n/s n/s
Cathepsin D-2 n/s n/s 3.99 0.25 n/s n/s
Cathepsin C-1 n/s n/s 3.28 1.16 n/s n/s
Cathepsin C-2 n/s n/s 5.14 5.30 n/s n/s
MAPK/ERK
Serine/threonine-protein
kinase 2
n/s n/s 5.03 2.65 n/s n/s
MAPK/ERK kinase kinase 5-1 n/s n/s -1.68 0.33 n/s n/s
C-Jun protein n/s n/s n/s n/s 3.99 1.62
MAPK/ERK kinase kinase 1-2 n/s n/s n/s n/s 1.87 0.46
MAPK kinase 9-2 n/s n/s n/s n/s 5.78 3.73
Transcripts represented were firstly selected for expression level (p < 0.01)
and then implication in biological processes related to PGN stimulation
(immune/inflammatory responses) during PGN-O111:B4. n/s: not signal, Mean:
Fold expression average (n = 3), SD: standard deviation.
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and Additional file 8). These results imply close similari-
ties with those previously obtained for trout macrophages
activated with crude LPS [56-59] suggesting a common
recognition mechanism distinct to that observed for
PGN-B4.
From transcripts identified as differentially expressed and
significantly up- or down-regulated (one-way ANOVA p <
0.01) we selected sixteen transcripts from the late stage for
qRT-PCR validation. All sixteen transcripts were signifi-
cantly expressed between the two PGNs and significantly
Table 2 Summary of selected transcripts expressed after challenges with PGN-K12
Early Median Late
Antigen presenttion Mean SD Mean SD Mean SD
MHC class I heavy chain-1 1.6 0.3 3.8 1.1 4.1 3.9
BPI binding protein 3.4 2.5 n/s n/s 1.5 0.6
Macrophage receptor MARCO n/s n/s n/s n/s 0.4 1.8
Cell adhesion and proliferation
Fibronectin receptor beta 11.6 11.3 n/s n/s n/s n/s
CD2 binding protein 1-1 2.9 1.1 n/s n/s n/s n/s
Matrix metalloproteinase 9 2.0 0.7 n/s n/s -4.7 1.8
Cytokines and Chemokines
Cytokine receptor gamma chain 1.7 0.5 n/s n/s n/s n/s
CC chemokine SCYA110-1 n/s n/s n/s n/s 1.2 0.1
Cellullar defense response
TNF receptor associated factor 1 n/s n/s 4.6 4.1 n/s n/s
NF-kappaB inhibitor alpha-1 4.6 4.3 n/s n/s n/s n/s
Cathepsin C-3 2.8 2.3 n/s n/s n/s n/s
Cathepsin D-1 3.2 2.8 n/s n/s 1.6 0.5
Cathepsin D-2 3.7 3.6 n/s n/s n/s n/s
MAPK/ERK
MAPK/ERK kinase kinase 6 1.7 0.3 2.1 0.5 n/s n/s
Serine/threonine-protein kinase 2 2.9 2.2 n/s n/s -1.2 0.1
Tyrosine-protein kinase FRK n/s n/s n/s n/s 1.7 0.5
Tyrosine-protein kinase SYK n/s n/s n/s n/s -2.0 1.4
Inflammatory response
Annexin A1-1 9.8 9.4 n/s n/s 1.4 0.3
Microsomal glutathione S-transferase 3 -1.6 0.2 -1.4 0.2 1.2 0.1
Arachidonate 5-lipoxygenase-1 -3.4 0.4 n/s n/s n/s n/s
Prostaglandine D synthase 1.3 0.1 n/s n/s n/s n/s
Angiotensin I converting enzyme 0.0 n/s n/s n/s 1.2 n/s
Cell homeostasis
Metallothionein A -4.4 1.1 n/s n/s 1.4 0.2
Heat shock 27 kDa protein-1 2.8 0.8 n/s n/s -1.8 0.6
Heat shock 70 kDa protein 1 3.0 1.4 n/s n/s -1.7 0.4
Glutathione reductase 2.0 0.8 n/s n/s -2.2 1.0
Cellular metabolism
Malate dehydrogenase, cytoplasmic 2.1 0.6 n/s n/s n/s n/s
Glucose-6-phosphate isomerase-1 n/s n/s n/s n/s 2.4 1.7
ATP synthase factor 6 2.4 1.7 n/s n/s n/s n/s
Transcription
Reverse transcriptase-like-2 2.4 1.7 -2.7 0.6 n/s n/s
CCAAT/enhancer binding protein beta n/s n/s 7.0 2.6 1.4 0.5
Chromatin dis-assembly
Transposase-15 -4.0 3.4 n/s n/s -1.3 0.3
Transposase-56 n/s n/s -3.4 0.5 n/s n/s
G1/S-specific cyclin D2 -3.1 2.0 -3.6 1.4 1.5 0.4
Transcripts represented were selected for expression level (p < 0.01) and then implication in biological processes related to PGN stimulation (immune/
inflammatory responses) during PGN-K12. n/s: no signal. Mean: Fold expression average (n = 3), SD: standard deviation.
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correlated when tested by qRT-PCR and Students-T test
(p < 0.05); thereby confirming the microarray results. FC
values obtain by microarray and qRT-PCR analyses are
listed in the additional file 2 (Student T tests p > 0.05).
Functional categories are associated with combinations of
PGN and time parameters
Analysis of function using GO annotations revealed that
most over-expressed transcripts were related to the
immune response and GO functional categories are speci-
fically influenced by a combinatorial PGN-Time effect
(Chi-square with Yates correction, p < 0.01, Figure 2). In
the early stage, different GO categories expressed were
PGN-dependent and include MHC class I receptor,
lysozome, NF-B cascade, peptidase activity, cell adhesion,
ribosome, or chromatin assembly or disassembly (Figure 2).
At the median stage the intensity of the PGN-B4 response
is highlighted by a set of biological processes specifically
associated to the immune response whereas only two GO
classes, cell adhesion and negative regulation of cell prolif-
eration, were represented with PGN-K12 (Figure 2). At
the late stage an inverse correlation was observed where
peptidase activity, complement activation, cell homeosta-
sis, and mitochondrial electron transport were highly
represented with PGN-K12 and NF-B cascade, protein-
MAPK cascade, and ribosome related to the PGN-O111:
B4 response (Figure 2). Remarkably, cell wall catabolism
was only observed with PGN-K12 and not during PGN-
O111:B4 challenge (Figure 2).
Characterisation of the prostaglandin response (time
course and dose response of PGN challenges)
Both COX-2 and PTGDS were identified by microarray
analyses as differentially expressed between the two
PGNs, therefore we measured both PGE2 and PGD2
release into the culture supernatant and in parallel
COX-2 and PTGDS mRNA abundance by qRT-PCR.
Analyses were done both in respect to response to
PGN-B4 and PGN-K12 over time (30 min, 1, 3, 6 and
12 h; Figure 3) and subsequently as a dose response
(0.1, 1 and 10 μg/mL; Figure 4).
Time course response assay (0, 30 min, 1, 3, 6, and 12 hrs
of PGN challenges)
COX-2 mRNA expression is strongly regulated by PGN-
B4 over time followed by a significant increase in PGE2
secretion into the culture medium. Stimulation with
PGN-K12 results in an increase of mRNA abundance at
1 h (two way ANOVA, F5, 35 = 8.678, p < 0.05, Figure
3a, Additional file 12) and a more gradual accumulation
of PGE2 in the culture medium in comparison with
PGN-B4. The dynamics of PTGDS mRNA expression
was time dependent (two way ANOVA, F5, 35 = 4.584,
p < 0.05, Figure 3a, Additional file 12) showing changes
a few minutes after stimulation with both PGNs
(30 min) and a strong increase 1 h post-treatment
(Figure 3a). The release of PGD2 was significantly differ-
ent (increasing) in PGN-B4 treated macrophages 6 h
after stimulation. Differences observed between PGE2 and
PGD2 release are correlated to both time and treatment
(two way ANOVA, F10, 54 = 4.553, p < 0.05, Figure 3b,
Additional file 12) where PGD2 has a low response, con-
centrations in the range of 1-14 pg/mL, when compared
with the PGE2 secretion, >200 pg/mL. PGE2 and PGD2
liberation patterns were strongly influenced by the
interaction between PGN and time (two way ANOVA,
F10, 54 = 2.522, p < 0.05, Figure 3b, Additional file 12).
Dose response assay (0.1, 1, and 10 μg/mL of PGN O111:
B4 and K12)
In dose response assays the expression pattern of COX-
2 mRNA induction was both dose and PGN-dependent
Figure 2 Qualitative and quantitative representations of biological processes (GO) over represented during challenges. Qualitative and
quantitative representations of over expressed GO categories (Chi-square with Yates correction p < 0.05). The corners of the spider-web maps
represent biological processes identified in the GO analysis. Different numbers of transcripts were grouped in each biological process. The
continuous mark lines (black or grey) represent the different number of transcripts in each biological process. The differences in the shape of the
GO pattern (continuous mark line) are due to divergence in the number of transcripts grouped to each Gene Class (biological process) under
both PGN challenges; the black line shows the GO pattern for PGN-O111:B4 and the grey line shows the GO pattern for PGN-K12 treatment.
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 7 of 13
(two way ANOVA, F5, 18 = 5.824, p < 0.05, Figure 4a,
Additional file 12). In figure 4a, a peak of COX-2
expression was registered at 10 μg/mL of PG-B4. Inter-
estingly, PGN-K12 stimulation generated a lower
expression of COX-2 mRNA (10 μg/mL; >50 fold) when
compared to PGN-B4 although at a dose of 1 μg/mL
fold changes are similar for both PGNs (Figure 4a). This
is reflected in PGE2 liberation where 10 μg/mL of PGN-
B4 generated a strong response (>600 fold increase;
PGN-interaction, two way ANOVA, F2, 48 = 182.588,
p < 0.05, Additional file 12) that correlated to increased
COX-2 mRNA abundance and all other concentrations
for both PGNs induced similar responses (>50 fold).
The liberation pattern of PGD2 was significantly depen-
dent upon PGN type, and showed a single increase at
10 μg/mL with PGN-B4 (Two way ANOVA, F2, 48 =
4.588, p < 0.05, Additional file 12). Surprisingly this is
not mirrored in PTGDS mRNA abundance levels where
PTGDS mRNA is significantly up-regulated by PGN-
K12 at 0.1 and 1 μg/mL and PGN-B4 at 1 μg/mL
(Figure 4b, Additional file 12).
Discussion
In recent studies on trout macrophages, peptidoglycan
(PGN-B4) was identified as a major pro-inflammatory
component of crude LPS preparations in which TLR4
and canonical TLR2 signalling pathways were discarded
as potential recognition systems for peptidoglycans [9].
As structural differences in PGN peptide moieties from
different bacterial-strains have been shown to modulate
host responses in both Drosophila and mammals
[32,36,38] we investigated, a priori with targeted micro-
array analysis, the effects of two different PGNs from
different strains of E. coli, O111:B4 and K12. These dif-
ferent serological features have been shown to affect the
host immune response [60]. A systematic dissection of
the impact of (combinations of) culture parameters
(time and treatment) revealed a significant re-modelling
Figure 3 Temporal characterisation of the prostaglandin response. Time course response to macrophages stimulated during 0, 30 min, 1, 3,
6, and 12 h with 10 μg/mL of PGN O111:B4 and K12. Experiments were performed in independent groups of PGN-stimulated (n = 3) or control
macrophage cultures (n = 9). a) COX-2 and PTGDS mRNA abundance over time in response to PGN-B4 (black bar) or PGN-K12 (white bar). Were
observed significative differences in the mRNA abundance between the times and treatments (PGNs) in both genes (two way ANOVA p < 0.01).
b) PGE2 and PGD2 release (pg/mL) stimulated by PGN-O111:B4 (black bars), PGN-K12 (white bars) and control (grey bars) into the culture
medium (n = 3/treatment). Were observed significative differences in the release between the times and treatments (PGNs or control) by both
prostaglandin (two way ANOVAs p < 0,01). The results are presents as fold change relative to 18S abundance and ± std deviation.
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of the trout macrophage transcriptome highlighting the
divergence of the response to the two different PGNs
(PGN-B4 vs. PGN-K12). As there were no other known
variables, the differences in the transcriptomic profile
are assumed to be solely due to the structure of the dif-
ferent PGNs and therefore differential recognition of
those by the macrophages. This assumption is supported
by the variation in transcript number (Figure 1a, 2),
their intensities (Figure 1a,b), and diversity (Table 1
and 2). In fish, modifications in the transcriptomic pro-
file have been observed in response to environmental
changes, stress and maintenance of the steady state of
transcriptional activity [61,62], or bidirectional transcrip-
tomic remodelling to inflammatory stimuli [56,63-67];
however, our data emphasises that macrophages respond
differentially to highly similar bacterial PGNs resulting
in a directed response i.e. prostaglandin release or a
more generalised ‘state of activation’.
In fish, the shift from a steady state to a functional
inflammatory state, i.e. secretion of pro-inflammatory
cytokines or PGE2, in trout macrophages stimulated
with crude LPS preparations has been shown to be dri-
ven mainly by gram negative PGN, where DNA and
RNA and ultra-pure LPS preparations are unable to
induce mRNA expression of pro-inflammatory cytokines
[9,68]. Our microarray analysis identified differential
regulation of both prostaglandin D-synthase (PTGDS)
and prostaglandin endoperoxide synthase-2 (COX-2)
that are directly involved in eicosanoid production;
PGD2 and PGE2 respectively [51,53] (Table 1 and 2).
COX-2 is regulated in macrophage/monocyte cell types
and is responsible for inflammatory prostaglandin,
PGE2, synthesis from arachidonic acid, and is involved
in cellular or tissue damage generated in acute and/or
chronic inflammatory states [69]. PTGDS metabolises
PGH2 to PGD2, [53,54,70,71] where PGD2 plays a role
Figure 4 Concentration dependence of the prostaglandin response. Dose response (0.1, 1, and 10 μg/mL) of trout macrophages to PGN
O111:B4 and K12 challenge. Experiments were performed overnight in independent macrophage cultures (n = 3). a) COX-2 and PTGDS mRNA
abundance (black bar) in response to different doses of PGN-O111:B4 or PGN-K12 (0.1, 1, 10 μg/mL). Were observed significative differences in
the mRNA abundance between different doses and treatments (PGNs) in both genes (two way ANOVAs p < 0.01). b) PGE2 and PGD2 release
(pg/mL) into the culture medium (grey bars). Were observed significative differences in the release between doses and treatments (PGNs or
control) by both prostaglandins (two way ANOVAs p < 0.01). The results are presented as fold change relative to 18S abundance and mean ±
std deviation.
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 9 of 13
during the injury process as vasodilator/constrictor or as
potent inflammatory mediator [72,73]. However, the
action of PGD2 in fish as a mediator of the immune
response is undefined. Downstream analyses, qRT-PCR
and prostaglandin release, of both COX-2 and PTGDS
mRNA regulation and PGH2 and PGD2 concentration
in supernatants reveals a strong correlation, both time
and dose-dependent, between PGN-type (B4 vs K12),
mRNA abundance and inflammatory outcome (Figure 4).
PGN-B4 is clearly a more potent regulator of the COX-
2 mRNA/PGE2 pathway where the activation threshold
for de novo synthesis of COX-2 is 10 μg/mL of PGN-B4.
Interestingly this threshold concentration has also been
observed on numerous occasions for pro-inflammatory
cytokine mRNA synthesis in trout macrophages
[9,39,46,68]. On the other hand, PTGDS mRNA synth-
esis appears as more dose sensitive for both PGNs with
a similar temporal expression pattern suggestive of a dif-
ferent signal transduction mechanism. However PGN-B4
stimulation at 10 μg/mL results in higher PGD2 secre-
tion. The regulation and biological effects of PGE2 and
PGD2 secretion in inflammatory responses in fish clearly
warrant more investigation.
In Drosophila the biological activity of a large panel of
natural and synthetic DAP-PGN showed significant varia-
bility in their stimulatory capacity and immune response
[74] and PGRP (peptidoglycan recognition protein) defi-
cient Drosophila are more susceptible to bacterial infec-
tions [75]. In human monocytes exposed to synthetic
muropeptides (peptide moiety of PGNs), TNF-a mRNA
expression and release was highly dependent upon struc-
tural modifications between peptides [38]. Thus inflamma-
tory outcomes are modified in accordance to sensitivity to
peptidoglycan structure. Such sensitivity is likely conferred
by the participation of different PRRs, PAMP-PRR interac-
tions or the accumulative signalling intensity (i.e. thresh-
old) of the group of PRRs involved in recognition.
Peptidoglycan recognition in mammals is mainly facili-
tated by three different PRR families; TLR2 (gram posi-
tive peptidoglycan), NOD2 and PGRPs all of which can
bind peptidoglycans [35,75,76]. TLR2 has been described
in fish species [77] although stimulation with lipoprotein
(Pam3CSK4), a classical TLR2-ligand, does not stimulate
an inflammatory response in our macrophage model [9].
However MyD88, an adaptor molecule involved in the
classical Drosophila or mammalian Toll signalling cas-
cades, which together with the receptor associated
kinase (IRAK) and TNF activated factor (TRAF6) allow
NF-B translocation to the nucleus (promoting expres-
sion of inducible inflammatory cytokines such as
TNF-a) during gram-negative bacterial infection
[46,78-80] was specifically up-regulated during PGN-
B4 stimulation. This suggests TLR involvement in
the PGN-mediated inflammatory response in trout
macrophages. Concerning PGRPs, PGRP-2, -5 and -6,
have been shown in the zebrafish to play an essential
role in defence during bacterial infections [30] and in
the trout PGRP-2 responds to PGN-B4 [9]. In this study
we also identified PGLYRP-6 (up-regulated; PGN-B4)
suggesting that the PGRPs also play a role in specific-
PGN recognition and this may be conserved throughout
the fishes.
In contrast to the specific directed response obtained
from PGN-B4 stimulation, PGN-K12 did not elicit a clear
functional response at the level of the macrophage tran-
scriptome or release of inflammatory mediators. A wide
diversity of transcripts were activated although at a
relatively low level. These results are similar to those
previously observed for stimulation with crude LPS pre-
parations in trout macrophages [[56], Boltaña et al.,
unpublished data] where both preparations can stimulate
the release of TNF-a into the culture medium [[68],
Roher et al., unpublished data]. Interestingly, TNF recep-
tor associated factor 1 was specifically induced by PGN-
K12. This transcript encodes a receptor-protein involved
in the activity of apoptotic pathways mediated by TNF-a
[80-82], however, we did not detect apoptosis during
the experimental period [MacKenzie et al, unpublished
data]. Moreover, the gene ontology category cell wall
catabolism was consistently over-expressed through-
out PGN-K12 treatment (Figure 2a,b) supporting the
existence of a strong transduction signal generated by
PGN-K12.
Conclusions
Our data highlights the significant differences observed
in macrophages responding to two PGNs derived from
different serotypes of the same bacteria. Responses at
the level of the transcriptome and the inflammatory out-
come (prostaglandin synthesis) highlight the different
sensitivity of the macrophage to slight differences (sero-
type) in peptidoglycan structure. Such divergent
responses are likely to involve differential receptor sensi-
tivity to ligands or indeed different receptor types. Such
changes in biological response will likely reflect upon
pathogenicity of certain serotypes and the development
of disease.
Additional material
Additional file 1: Specific primers used for quantitative qRT-PCR
(sequence and accession number).
Additional file 2: Comparison of expression data for selected
transcripts obtained from microarray analyses and qRT-PCR
validation. The results are presented as fold change relative to 18S
abundance and mean ± std deviation.
Additional file 3: Description of PGN (O111;B4) regulated
transcripts/genes over the control (all cDNAs on the array) at early
stage (1 h).
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 10 of 13
Additional file 4: Description of PGN (O111;B4) regulated
transcripts/genes over the control (all cDNAs on the array) at
median stage (6 h). xls
Additional file 5: Description of PGN (O111;B4) regulated
transcripts/genes over the control (all cDNAs on the array) at late
stage (12 h). xls
Additional file 6: Description of PGN (K12) regulated transcripts/
genes over the control (all cDNAs on the array) at early stage (1 h).
Additional file 7: Description of PGN (K12) regulated transcripts/
genes over the control (all cDNAs on the array) at median stage (6 h).
Additional file 8: Description of PGN (K12) regulated transcripts/
genes over the control (all cDNAs on the array) at late stage (12 h).
Additional file 9: Quantitative summary of transcripts/genes
differentially expressed over the control in both treatment and
stages.
Additional file 10: Relationship between intensity and magnitude of
transcriptomic response in up (a) and down (b) regulated genes at
different time stages during the PGNs challenge. The horizontal
abscises (magnitude) show the number of transcripts grouped in
biological processes expressed in both treatments as: Antigen
presentation, Cell adhesion and proliferation, Cytokines and Chemokines,
Cellullar defense response, MAPK/ERK, Inflammatory response, Cell
homeostasis, Transcription. The vertical abscises (intensity) show fold
change mean (FC: intensity) of the transcripts grouped in each biological
process. The black circle and the blue slope represented the fit
generated by the intensity and magnitude of the transcriptomic
response under PGN-O111:B4 treatment. The white circle and the red
slope represented the fit generated by the intensity and magnitude of
the transcriptomic response under PGN-K12 treatment. Transcriptomic
profiles were highly ranked dependent upon PGN-type (two-way
ANCOVA on transcriptomic magnitudes of respective intensities a = 0.05;
n = 68).
Additional file 11: Summary of ANCOVA analysis for common slope
of regression and adjusted means examining differences in
intensity and magnitude of the transcriptomic response at different
times (1, 6 and 12 h; n = 68).
Additional file 12: Summary of multiple comparisons of two way
ANOVAS.
Abbreviations
PAMPs: pathogen-associated molecular patterns; PGN: peptidoglycans;
PGRPs: peptidoglycan recognition proteins; GDE: differentially expressed
genes; COX-2: Cyclooxygenase 2; PTGDS: prostaglandin D synthase.
Acknowledgements
This study was supported by the Consolider-Ingenio Programme 2010,
project CSD2007-0002 funded by the Spanish Ministry of Science and
Education, Spain to SM.
Author details
1Institute of Biotechnology and Biomedicine, Universitat Autónoma de
Barcelona, 08193 Barcelona, Spain. 2Departamento de Biologia, Universidad
de Santiago de Chile, Santiago de Chile, Chile. 3Great Lakes WATER Institute,
600 E. Greenfield Ave., Milwaukee, WI 53204, USA.
Authors’ contributions
SM, SB and FG participated in the conception of the experimental design. SB
and SM carried out the analysis. SB, FRL and DM performed microarray
experiments. SB edited expression data, carried all statistical analysis and
validated array data with qRT-PCR. SB and SM wrote the manuscript and FG
corrected it. All listed authors edited the manuscript. All authors read and
approved the manuscript.
Received: 16 June 2010 Accepted: 14 January 2011
Published: 14 January 2011
References
1. Kopp E, Medzhitov R: Recognition of microbial infection by Toll-like
receptors. Curr Opin Immunol 2003, 15:396-401.
2. Kabelitz D, Medzhitov R: Innate immunity cross-talk with adaptive
immunity through pattern recognition receptors and cytokines. Curr
Opin Immunol 2007, 19:1-3.
3. Gupta D, Kirkland TN, Viriyakosol S, Dziarski R: CD14 Is a Cell-activating
Receptor for Bacterial Peptidoglycan. J Biol Chem 1996,
271(38):23310-23316.
4. Dziarski R, Tapping RI, Tobias PS: Binding of Bacterial Peptidoglycan to
CD14. J Biol Chem 1998, 273(15):8680-8690.
5. Dziarski R, Viriyakosol S, Kirkland TN, Gupta D: Soluble CD14 Enhances
Membrane CD14-Mediated Responses to Peptidoglycan: Structural
Requirements Differ from those for Responses to Lipopolysaccharide.
Infect Immun 2000, 68(9):5254-5260.
6. Schrijver IA, Melief MJ, Eulderink F, Hazenberg MP, Laman JD: Bacterial
Peptidoglycan Polysaccharides in Sterile Human Spleen Induce
Proinflammatory Cytokine Production by Human Blood Cells. J Infect Dis
1999, 179:1459-1468.
7. Rabehi L, Irinopoulou T, Cholley B, Heaffner-Cavaillon N, Carreno MP: Gram-
Positive and Gram-Negative Bacteria Do Not Trigger Monocytic Cytokine
Production through Similar Intracellular Pathways. Infect Immun 2001,
69(7):4590-4599.
8. Iliev DB, Liarte CQ, Mackenzie S, Goetz FW: Activation of rainbow trout
(Oncorhynchus mykiss) mononuclear phagocytes by different pathogen
associated molecular pattern (PAMP) bearing agents. Mol Immunol 2005,
42:1215-1223.
9. Mackenzie S, Roher N, Boltaña S, Goetz FW: Peptidoglycan, not endotoxin,
is the key mediator of cytokine gene expression induced in rainbow
trout macrophages by crude LPS. Mol Immunol 2010, 47:1450-1457.
10. Dziarski R, Gupta D: Role of MD-2 in TLR2-and TLR4-mediated recognition
of Gram-negative and Gram-positive bacteria and activation of
chemokine genes. Innate Immun 2000, 6:401-405.
11. Dziarski R, Gupta D: Staphylococcus aureus Peptidoglycan Is a Toll-Like
Receptor 2 Activator: a Reevaluation. Infect Imm 2005, 78(8):5212-5216.
12. Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann C:
Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis:
receptors, signal transduction, biological effects, and sinergismo. Shock
2003, 20(5):402-414.
13. Xu Z, Dziarski R, Wang Q, Swartz K, Sakamoto KM, Gupta D: Bacterial
Peptidoglycan-Induced tnf- Transcription Is Mediated Through the
Transcription Factors Egr-1, Elk-1, and NF-. J Immunol 2001,
167(12):6975.
14. Weidemann B, Schletter J, Dziarski R, Kusumoto S, Stelter F, Rietschel ET,
Flad HD, Ulmer AJ: Specific Binding of Soluble Peptidoglycan and
Muramyldipeptide to CD14 on Human Monocytes. Infect Imm 1997,
65(3):858-864.
15. Dziarski R, Tapping RI, Tobias PS: Binding of Bacterial Peptidoglycan to
CD14. J Biol Chem 1998, 273(15):8680-8690.
16. Gupta D, Wang Q, Vinson CH, Dziarski R: Bacterial Peptidoglycan Induces
CD14-dependent Activation of Transcription Factors CREB/ATF and AP-1.
J Biol Chem 1999, 274(20):14012-14020.
17. Mathison JC, Tobias PS, Wolfson E, Ulvevitch RJ: Plasma lipopolysaccharide
(LPS)-Binding protein. A Key Component in macropophage Recognition
of Gram-Negative LPS. J Immunol 1992, 149(1):200-206.
18. Dziarski R: Recognition of bacterial peptidoglycan by the innate immune
system. Cell Mol Life Sci 2003, 60:1793-1804.
19. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ:
Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated
by toll-like receptor 2. J Biol Chem 1999, 274(25):17406-17419.
20. Schröder N, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U,
Gobel U, Weber J, Schumann RRalf: Lipoteichoic Acid (LTA) of
Streptococcus pneumoniae and Staphylococcus aureus Activates
Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding
Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved.
J Biol Chem 2003, 278(18):15587-15594.
21. Chamaillard M, Girardin S, Viala J, Philpott D: NODs, Nalps and Naip:
intracellular regulators of bacterial-induced inflammation. Cell Microbiol
2003, 5:581-592.
22. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G,
Philpott DJ, Sansonetti PJ: Nod2 Is a General Sensor of Peptidoglycan
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 11 of 13
through Muramyl Dipeptide (MDP) Detection. J Biol Chem 2003,
278(11):8869-8872.
23. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, Tedin K,
Taha MK, Labigne A, Zaehringer U, Coyl AJ, Di Stefano PS, Bertin J,
Sansonetti PJ, Philpott DJ: Nod1 Detects a Unique Muropeptide from
Gram-Negative Bacterial Peptidoglycan. Science 2003, 300:1584-1587,
2003.
24. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K,
Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-
Luna JS, Nuñez G: Host Recognition of Bacterial Muramyl Dipeptide
Mediated through NOD2. J Biol Chem 2003, 278:5509-5512.
25. Kang D, Liu G, Lundstrom A, Gelius E, Steiner H: A peptidoglycan
recognition protein in innate immunity conserved from insects to
humans. Proc Natl Acad Sci USA 1998, 95:10078-10082.
26. Werner T, Liu G, Kang D, Ekengren S, Steiner H, Hultmark D: A family of
peptidoglycan recognition proteins in the fruit fly Drosophila
melanogaster. Proc Natl Acad Sci USA 2000, 97:13772-13777.
27. De Gregorio E, Spellman PT, Rubin GM, Lemaitre B: Genome-wide analysis
of the Drosophila immune response by using oligonucleotide
microarrays. Proc Natl Acad Sci USA 2001, 98:12590-12595.
28. De Gregorio E, Spellman P, Tzou P, Rubin GM, Lematrie B: The Toll and
Imd pathways are the major regulators of the immune response in
Drosophila. EMBO Journal 2002, 21(11):2568-2579.
29. Boutros M, Agaisse H, Perrimon N: Sequential Activation of Signaling
Pathways during Innate Immune Responses in Drosophila. Dev Cell 2002,
3:711-722.
30. Li X, Wang S, Qi J, Echtenkamp SF, Chatterjee R, Wang M, Boons G,
Dziarski R, Gupta D: Zebrafish Peptidoglycan Recognition Proteins Are
Bactericidal Amidases. Nature Rev Immunol 2007, 2:725-734.
31. Ghuysen JM: Use of Bacteriolytic Enzymes in Determination of Wall
Structure and Their Role in Cell Metabolism. Bacteriol Rev 1968,
32(4):425-464.
32. Schleifer KH, Kandler O: Peptidoglycan types of bacterial cell walls and
their taxonomic implications. Bacteriol Rev 1972, 36:407-77.
33. Jenni R, Berger-Bächi B: Teichoic acid content in different lineages of
Staphylococcus aureus NCTC832. Arch Microbiol 1998, 170:171-178.
34. Deininger S, Stadelmaier A, Von Aulock S, Morath S, Schmidt RR, Hartung T:
Definition of structural prerequisites for lipoteichoic acid-inducible
cytokine induction by synthetic derivatives. J Immunol 2003,
170:4134-4138.
35. Boneca IG: The role of peptidoglycan in pathogenesis. Curr Opin Microbiol
2005, 8:46-53.
36. Kumar S, Roychowdhury A, Ember B, Wang Q, Guan R, Mariuzza RA,
Boons GJ: Selective recognition of synthetic lysine and meso-
diaminopimelic acid-type peptidoglycan fragments by human
peptidoglycan recognition proteins. J Biol Chem 2005, 280:37005-37012.
37. Wolfert MA, Murray TF, Boons GJ, Moore JN: The Origin of the Synergistic
Effect of Muramyl Dipeptide with Endotoxin and Peptidoglycan. J Biol
Chem 2002, 277(42):39179-39186.
38. Wolfert MA, Roychowdhury A, Boons GJ: Modification of the Structure of
Peptidoglycan Is a Strategy To Avoid Detection by Nucleotide-Binding
Oligomerization Domain Protein 1. Infect Immun 2007, 75(2):706-713.
39. Mackenzie S, Planas JV, Goetz FW: LPS-stimulated expression of a tumor
necrosis factor-alpha mRNA in primary trout monocytes and in vitro
differentiated macrophages. Dev Comp Immunol 2003, 27:393-400.
40. Koskinen H, Pehkonen P, Vehniainen E, Krasnov A, Rexroad C, Afanasyev S,
Molsa H, Oikari A: Response of rainbow trout transcriptome to model
chemical contaminants. Biochem Biophys Res Commun 2004, 320:745-753.
41. Krasnov A, Koskinen H, Pehkonen P, Rexroad CE, Afanasyev S, Molsa H:
Gene expression in the brain and kidney of rainbow trout in response
to handling stress. BMC Genomics 2005, 6(1):3-18.
42. Cleveland WS, Grosse E, Shyu WM: Local regression models. In Statistical
Models. Edited by: Chambers JM, S TJHE. Pacific Grove, Wadsworth and
rooks/Cole; 1999:309-376.
43. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proceedings of the National Academy of Sciences of the United States of
America 2003, 100(16):9440-9445.
44. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 2000, 25(1):25-29.
45. Pfaffl MW: A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 2001, 29:45-53.
46. Iliev DB, Roach KC, Mackenzie S, Planas JV, Goetz FW: Endotoxin
recognition: In fish or not in fish? FEBS Letters 2005, 579:6519-6528.
47. Kraal G, Luc JW, Laan V, Eloma O, Tryggvason K: The macrophage receptor
MARCO. Microbes Infect 2000, 2:313-316.
48. Hebert H, Jegerschöld C: The structure of membrane associated proteins
in eicosanoid and glutathione metabolism as determined by electron
crystallography. Curr Opin Struc Biol 2007, 17(4):396-404.
49. Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C,
Chow EP, Browning JL, Ramachandran KL, Pepinsky B: Cloning and
expression of human lipocortin, a phospholipase A2 inhibitor with
potential anti-inflammatory activity. Nature 1986, 320:77-81.
50. Saunders L, Perkins R, Balachandran D, Michaels S, Ford R, Mayeda R,
Barber A: Characterization of two evolutionarily conserved, alternatively
spliced nuclear phosphoproteins, NFAR-1 and -2, that function in
mRNA processing and interact with the double-stranded RNA-
dependent protein kinase, PKR. J. Biological Chem 2001,
276:32300-32312.
51. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA
1992, 89:7384-7388.
52. Tazawa R, Xu XM, Wu KK, Wang LH: Characterization of the Genomic
Structure, Chromosomal Location and Promoter of Human Prostaglandin
H Synthase-2 Gene. Biochem Bioph Res Co 1994, 203(1):190-199.
53. Shimizu T, Yamamoto S, Hayaishi O: Purification and properties of
prostaglandin D synthetase from rat brain. J Biol Chem 1979,
254:5222-5228.
54. Nagata A, Suzuki Y, Igarashi M, Eguchi N, Toho H, Urade Y, Hayaishi O:
Human brain prostaglandin D synthase has been evolutionarily
differentiated from lipophilic-ligand carrier proteins. Proc. Nati. Acad. Sci.
USA 1991, 88:4020-4024.
55. Kambris Z, Jang BS, Nam IH, Romeo HJ, Takahashi Y, Lee K, Ueda WJ,
Lemaitre B: Drosophila immunity: a large-scale in vivo RNAi screen
identifies five serine proteases required for Toll activation. Curr Biol 2006,
16:808-813.
56. Mackenzie S, Balasch JC, Novoa B, Ribas L, Roher N, Krasnov A, Figueras A:
Comparative analysis of the acute response of the trout, O. mykiss, head
kidney to in vivo challenge with virulent and attenuated infectious
hematopoietic necrosis virus and LPS-induced inflammation. BMC
Genomics 2008, 9:141-156.
57. Goetz FW, Planas JV, Mackenzie S: Tumor necrosis factors. Dev Comp
Immunol 2004, 28:487-497.
58. Mackenzie S, Montserrat N, Mas M, Acerete L, Tort L, Krasnov A, Goetz FW,
Planas JV: Bacterial lipopolysaccharide induces apoptosis in the trout
ovary. Reprod Biol Endocrin 2006, 4:46-58.
59. Mackenzie S, Iliev D, Liarte C, Koskinen H, Planas JV, Goetz FW, Molsä H,
Krasnov A, Tort L: Transcriptional analysis of LPS-stimulated activation of
trout (Oncorhynchus mykiss) monocyte/macrophage cells in primary
culture treated with cortisol. Molec Immun 2006, 43(9):1340-1348.
60. Barclay GR, Scott BB: Serological Relationships between Escherichia coli
and Salmonella smooth- and rough-mutant lipopolysaccharides as
revealed by enzyme-linked immunosorbent assay for human
immunoglobulin G Antiendotoxin Antibodies. Innate Immun 1987,
55(11):2706-2714.
61. Bayne CJ, Gerwick L, Wheeler PA, Thorgaard GH: Transcriptome profiles of
livers and kidneys from three rainbow trout (Oncorhynchus mykiss)
clonal lines distinguish stocks from three allopatric populations. Com
Biochem Physiol 2006, 1:396-403.
62. Roberge C, Einum S, Guderley H: Bernatchez Rapid parallel evolutionary
changes of gene transcription profiles in farmed Atlantic salmon. Mol
Ecol 2006, 15:9-20.
63. Doñate , Balasch JC, Callol A, Bobe J, Tort L, Mackenzie S: The effects of
immunostimulation through dietary manipulation in the rainbow trout;
evaluation of mucosal immunity. Mar Biotechnol 2010, 12(1):88-99.
64. Byon JY, Ohira T, Hirono I, Aoki T: Use of a cDNA microarray to study
immunity against viral hemorrhagic septicemia (VHS) in Japanese
flounder (Paralichthys olivaceus) following DNA vaccination. Fish Shellfish
Immunol 2005, 18:135-147.
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 12 of 13
65. Martin S, Blaney SC, Houlihan DF, Secombes CJ: Transcriptome response
following administration of a live bacterial vaccine in Atlantic salmon
(Salmo salar). Mol Immunol 2006, 43:1900-1911.
66. Jorgensen SM, Afanasyev S, Krasnov A: Gene expression analyses in
Atlantic salmon challenged with infectious salmon anemia virus reveal
differences between individuals with early, intermediate and late
mortality. BMC Genomics 2008, 9:179-186.
67. Aluru N, Vijayan MM: Stress transcriptomics in fish: A role for genomic
cortisol signaling. Gen Com Endoc 2009, 164:142-150.
68. Roher N, Callol A, Planas J, Goetz F, Mackenzie S: Endotoxin recognition in
fish results in inflammatory cytokine secretion not gene expresión.
Innate Immun 2010, 10:245-267.
69. Hinz B, Brune K: Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther
2002, 300(2):367-375.
70. Chen BC, Liao CC, Hsu MJ, Liao YT, Lin CC, Sheu JR, Lin CH: Peptidoglycan-
induced IL-6 production in RAW 264.7 macrophages is mediated by
cyclooxygenase-2, PGE2/PGE4 receptors, protein kinase A, I kappa B
kinase, and NF-kappa B. J. Immunol 2006, 177:681-693.
71. Chen BC, Kang JC, Lu YT, Hsu MJ, Liao CC, Chiu WT, Yeh FL, Lin CH: Rac1
regulates peptidoglycan-induced nuclear factor-kappaB activation and
cyclooxygenase-2 expression in RAW 264.7 macrophages by activat- ing
the phosphatidylinositol 3-kinase/Akt pathway. Mol. Immunol 2009,
46:1179-1188.
72. Urade Y, Hayaishi O: Prostaglandin D synthase: Structure and function.
Vitam Horm 2000, 58:89-120.
73. Kanaoka Y, Urade Y: Hematopoietic prostaglandin D synthase.
Prostaglandins Leukot Essent Fat Acids 2003, 69(3):163-167.
74. Stenbak C, Ryu J, Leulier F, Pili-Floury S, Parquet C, Herve M, Chaput C,
Boneca I, Lee W, Lemaitre B, Mengin-Lecreulx D: Peptidoglycan molecular
requirements allowing detection by the Drosophila immune deficiency
pathway. J. Immunol 2004, 173:7339-7348.
75. Royet J, Dziarski R: Peptidoglycan recognition proteins: pleiotropic
sensors and effectors of antimicrobial defences. Nature Rev Microbiol
2007, 5(4):267-277.
76. McDonald C, Inohara N, Nuñez G: Peptidoglycan Signaling in Innate
Immunity and Inflammatory Disease. J Biol Chem 2005,
280(21):20177-20180.
77. Baoprasertkul P, Peatman E, Abernathy J, Liu Z: Structural characterisation
and expression analysis of Toll-like receptor 2 gene from catfish. Fish
Shellfish Immun 2007, 22(4):418-426.
78. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim S, Goode J, Lin P,
Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B: Identification of
Lps2 as a key transducer of MyD88-independent TIR signalling. Nature
2003, 424:743-748.
79. Jiang Z, Georgel P, Du X, Shamel L, Sovath L, Mudd S, Huber M, Kalis C,
Keck S, Galanos C, Freudenberg M, Beutler B: CD14 is required for MyD88-
independent LPS signaling. Nature Immunol 2005, 6(6):565-573.
80. Akira S: Mammalian Toll-like receptors. Curr opin 2003, 15:5-11.
81. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell 2001, 104(4):487-501.
82. Cha GH, Cho KS, Lee JH, Kim M, Kim E, Park J, Lee SB, Chung J: Discrete
Functions of TRAF1 and TRAF2 in Drosophila melanogaster Mediated by
c-Jun N-Terminal Kinase and NF-B-Dependent Signaling Pathways. Mol
Cell Biol 2003, 23(22):7982-7991.
doi:10.1186/1471-2164-12-34
Cite this article as: Boltaña et al.: Divergent responses to peptidoglycans
derived from different E. coli serotypes influence inflammatory outcome
in trout, Oncorhynchus mykiss, macrophages. BMC Genomics 2011 12:34. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boltaña et al. BMC Genomics 2011, 12:34
http://www.biomedcentral.com/1471-2164/12/34
Page 13 of 13
